This directory serves as a resource listing of active biotech that develop therapeutics, diagnostics and/or medtech. The companies listed in this directory are not representative of the companies that are active members of the Biotech and Money community.
Add / Amend your company listing for free
(only active biotech ie. therapeutic, diagnostic and medtech companies are eligible for listing)
Israel
Alcobra Ltd. is an emerging biopharmaceutical company primarily focused on the development and commercialization of a proprietary drug, MG01CI, to treat Attention Deficit Hyperactivity Disorder, or ADHD.
Andromeda Biotech is focused on the development of an innovative treatment for autoimmune diabetes. The Company's lead product, DiaPep277 presents a novel therapeutic approach for treating type 1 diabetes by immunomodulating the immune system.
Applied Immune Technologies (AIT) is a drug development company specializing in T-Cell Receptor-Like (TCRL) antibodies that are targeted to intracellular-derived peptides for a variety of therapeutic and diagnostic applications. AIT's core technology platforms encompass the identification and validation of novel MHC-based targets, as well as development of therapeutic Human Recombinant T-Cell Receptor-Like (TCRL) antibodies with the unique ability to bind with these intracellular peptide/MHC complexes with the specificity of cytotoxic T-cell killer cells.
Aspireo Pharmaceuticals Ltd is a biopharmaceutical company focused on the development of a novel somatostatin analog (SSA) for the treatment of diseases resulting from hormone-active tumors, such as acromegaly, neuroendocrine and gastroenteropancreatic tumors, Cushing?s Disease and diabetic retinopathy. Aspireo?s sole development compound is Somatoprim (DG3173), a novel and proprietary somatostatin analog that is based on a novel amino acid composition and a unique backbone cyclization technology used for stabilization of the peptide.
Atox Bio is a clinical stage biotechnology company that develops novel immunemodulators in areas of major unmet need with a focus on critical care. AB103, Atox Bio?s lead product, is being developed for severe infections in critically ill patients . AB103 completed a phase 2 study in patients with Necrotizing Soft Tissue Infections (NSTI).
Avraham Pharmaceuticals (Israel) is a clinical-stage small molecule company focused on the treatment of Alzheimer?s disease and mild cognitive impairment (MCI)
BTG develops and manufactures biopharmaceuticals based on genetic engineering and other biotechnologies. Engaged in the development and manufacture of human health care products derived from genetic engineering and biotechnology processes, the company also offer a wide range of well integrated CMO-type services and activities.
Biokine is a biopharmaceutical company developing novel drugs in the fields of cancer treatment and Inflammation Biokine Therapeutics Ltd. (Biokine) lead product- BKT140, is a CXCR4 antagonist with an outstanding stem-cells mobilizing activity. CXCR4 targets stem cells mobilization and collection in Multiple Meyaloma (MM) and Non Hodgin's Lymphoma (NHL) patients undergoing auto-transplantation post high dose chemotherapy treatment.
BioLineRx Ltd. is a publicly-traded bio-pharmaceutical development company. It is dedicated to building a portfolio of products for unmet medical needs or with advantages over currently available therapies.
BioLineRx's Business Model is based on the in-licensing of early stage molecules from biotechnology incubators and technology transfer offices. The company then evaluates potential drug candidates via feasibility assessment. For molecules or devices exhibiting both therapeutic and market edge, the company engages in pre-clinical and clinical studies. Following a successful series of clinical trials, the Company partners with medium and large pharmaceutical companies for the accomplishment of last phase clinical study and commercialization
Its current portfolio consists of six clinical stage candidates: BL-1040 for prevention of pathological cardiac remodeling following a Myocardial infarction, was out-licensed to Ikaria Inc. and commencing a pivotal study ; BL-7040 for treating Inflammatory Bowel Disease (IBD) has recently completed a successful Ph IIa study; BL-8040 starting a Ph II for treatment of hematological cancers in the US and Israel; BL-5010 for skin lesion removal about to start a Ph II study in Europe; BL-8020 starting a Ph I/II study in Hepatitis C and BL-1021 for neuropathic pain is in Phase I development. In addition, numerous products are in various pre-clinical stages for a variety of indications, including respiratory, central nervous system diseases, oncology, infectious diseases, cardiovascular and autoimmune diseases.
BioLineRx's Business Model is based on the in-licensing of early stage molecules from biotechnology incubators and technology transfer offices. The company then evaluates potential drug candidates via feasibility assessment. For molecules or devices exhibiting both therapeutic and market edge, the company engages in pre-clinical and clinical studies. Following a successful series of clinical trials, the Company partners with medium and large pharmaceutical companies for the accomplishment of last phase clinical study and commercialization
Its current portfolio consists of six clinical stage candidates: BL-1040 for prevention of pathological cardiac remodeling following a Myocardial infarction, was out-licensed to Ikaria Inc. and commencing a pivotal study ; BL-7040 for treating Inflammatory Bowel Disease (IBD) has recently completed a successful Ph IIa study; BL-8040 starting a Ph II for treatment of hematological cancers in the US and Israel; BL-5010 for skin lesion removal about to start a Ph II study in Europe; BL-8020 starting a Ph I/II study in Hepatitis C and BL-1021 for neuropathic pain is in Phase I development. In addition, numerous products are in various pre-clinical stages for a variety of indications, including respiratory, central nervous system diseases, oncology, infectious diseases, cardiovascular and autoimmune diseases.
BioMarCare?s mission is to develop a cluster of high value tumor biomarkers (biological indicators) for pre-cancer alert, early detection and prediction of colorectal cancer (CRC) risk and response. We aim to provide a revolutionary blood test for determining an individual?s current risk for having colorectal cancer and personalized medicine for evaluating potential treatment options, significantly improving the outcome.
BiondVax is a publicly traded (TASE: BNDX), advanced clinical stage biotech company dedicated to improving protection against influenza, with its lead product a universal influenza (flu) vaccine called Multimeric-001. BiondVax's universal flu vaccine is designed to protect against all A and B flu strains, present and future, seasonal and pandemic, as it triggers our immune defenses to recognize conserved and common parts of the virus.